Abstract
Hematopoietic cell transplantation (HSCT) offers the most effective therapy for patients with myclodysplastic syndromes (MDS) who have a human leukocyte antigen (HLA)-matched sibling donors and results have improved progressively over the past decade. For patients without an HLA-matched donor,volunteer unrelated donor(VUD) HSCT, unrelated cord blood allogeneic stem cell transplantation (CBT) and autologous HSCT may be the alternative. In this review the indication of transplantation and the prognostic factors for outcome after HSCT including patient age, timing of transplantation, induction chemotherapy before HSCT, conditioning regimens, source of stem cell were analysed. Key words: Myelodysplastic syndromes; Hematopoietic stem cell trantsplantation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
